Page 15 - Affimed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) Press Release: Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares Heidelberg, Germany, January 15, 2021 -- Affimed N.V. ("Affimed" or the "Company") (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the closing of its previously announced public offering of 16,666,667 common shares, at the public offering price of $6.00 per share, and the exercise in full by the underwriters of their option to purchase an ad...

Message : Required fields Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 16,666,667 of its common shares at a public offering price of $6.00 per common share. In addition, Affimed has granted the underwriters a 30-day over-allotment option to purchase up to 2,500,000 common shares at the public offering price less underwriting discounts. After dedu...

Latest updates on this topic from reliable sources.